Name: Latest research reports of Zydus Lifesciences Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Phillip Capital

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

922.4000 5.50 (0.60%)

NSE Jan 05, 2026 12:44 PM

Volume: 208.4K

Zydus Lifesciences Ltd.

16 May 2016

922.40

0.60%

Cadila Q4FY16 Update 16May2016

Buy: Zydus Lifesciences Ltd.

Recommendation

Phillip Capital

9 JV business saw strong 25%/14% growth for Q4/FY16. However, it guides for flattish revenueperformancefromitsJVbusinessinFY17 9 CDHindicatestocompletelargepartofremedialactionsbyMay2016atitsproblematic...

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.